Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) is seeking approval for additional indication of Synflorix, a paediatric pneumococcal vaccine, in the Europe.
Subscribe to our email newsletter
The additional indication is for the active immunisation against pneumonia caused by Streptococcus pneumoniae in infants and children from six weeks up to five years of age.
The company has submitted the application as a variation to the marketing authorisation application to the European Medicines Agency.
Synflorix is at present approved in the EU and 90 other countries for active immunisation against invasive disease and acute otitis media caused by Streptococcus pneumoniae in infants and children from six weeks up to five years of age.
In 67 countries of the 90, Synflorix is approved for pneumonia while it is not approved for use in the US.